Alexza Pharmaceuticals Inc.
Pioneering Targeted Drug Delivery through Aerosol Advancements

Alexza Pharmaceuticals has established itself as a leading force in pharmaceutical innovation for over two decades, driven by a strong commitment to developing novel drug delivery methods. At the core of this innovative drive is the revolutionary Staccato One Breath Technology (OBT), an aerosol drug delivery system. This groundbreaking system has shown remarkable efficacy in treating central nervous system (CNS) disorders, representing a significant departure from conventional methods.

It employs a hand-held inhaler that efficiently transports medication into the lungs, facilitating rapid systemic distribution. This technology is especially pivotal for conditions necessitating immediate medical response, offering swift and effective treatment solutions.

“Our technology is akin to a non-invasive intravenous shot, swiftly delivers drugs to the lungs for rapid onset of effects, catering to diseases that benefit from immediate treatment,” states Dan Myers, VP of Product Research and Development at Alexza Pharmaceuticals.

Alexza’s commitment to innovation is exemplified by its dedication to refining drug particle sizes and ensuring precise delivery of therapeutic agents to the lungs. The Staccato OBT system, a prime example of this approach, employs pure, excipient-free drugs applied as a film on a metallic substrate. This substrate is heated during inhalation, transforming the drug film into gas, which then condenses into fine aerosol particles. This process enhances absorption and penetration into the lungs, setting a new standard in drug delivery technology.

A key attribute of the Staccato OBT system is its streamlined administration process. Patients can engage in slow, deep breaths to activate the heating mechanism, contrasting the more complex mechanical procedures, device assembly and cleaning, or massive inspiratory efforts associated with traditional aerosol technologies like metered dose inhalers, nebulizers, and dry powder inhalers.

A notable success in Alexza’s product line is ADASUVE, an inhalation powder designed for managing agitation in patients with schizophrenia and bipolar disorder. In contrast to the conventional approach of using injectable sedatives, which carries risks for both patients and healthcare providers, ADASUVE offers a non-invasive solution. Administered with a single inhalation, its rapid effects provide calming and sedative benefits within minutes. This ease of use and quick action has garnered positive feedback from medical professionals and patients, significantly enhancing the patient experience.

The relevance of Alexza’s technology extends further in treating acute conditions like epilepsy or migraines, where swift intervention is critical. Its advanced delivery system ensures that medication enters the bloodstream rapidly, offering faster relief than oral formulations. This capability to provide timely treatment is a testament to the company’s innovative edge and a significant factor in improving patient outcomes and quality of life.

“Our value lies in addressing acute conditions promptly, ensuring timely relief and effective treatment,” says Tatjana Naranda, President and COO of Alexza Pharmaceuticals.

The firm also has a multidisciplinary team with expertise in chemistry, formulations, analytical chemistry, mechanical and electrical engineering, regulatory affairs, clinical trials, quality control, and manufacturing. This diverse team ensures the successful development, manufacturing, and regulatory compliance of Alexza’s products. In addition, with a new state-of-the-art facility and vast production experience, Alexza is well-positioned to meet market demands.

There are several innovative drugs in Alexza’s pipeline, including apomorphine for off episodes in patients with Parkinson’s disease and granisetron for cyclic vomiting syndrome. By leveraging its technology and device platforms, Alexza aims to deliver multiple drugs efficiently and effectively.

Alexza stands at the front line of improving patient outcomes by adopting a user-friendly approach that also assures rapid onset of action and precise drug delivery. Its expertise in chemistry, aerosol science, and device design, combined with a dedicated and diverse team, positions Alexza as a potential disruptor, garnering significant attention in the medical community.